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Copyright © 2011 JCBN 2011 This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unre- stricted use, distribution, and reproduction in any medium, pro- vided the original work is properly cited. Glucose is an energy substrate, as well as the primary source of
nucleotide sugars, which are utilized as donor substrates in protein
glycosylation. Appropriate glycosylation is necessary to maintain
the stability of protein, and is also important in the localization
and trafficking of proteins. The dysregulation of glycosylation
results in the development of a variety of disorders, such as cancer,
diabetes mellitus and emphysema. Glycosylation is kinetically
regulated by dynamically changing the portfolio of glycosyltrans 
ferases, nucleotide sugars, and nucleotide sugar transporters,
which together form a part of what is currently referred to as
the “Glycan cycle”. An excess or a deficiency in the expression of
glycosyltransferases has been shown to alter the glycosylation
pattern, which subsequently leads to the onset, progression and
exacerbation of a number of diseases. Furthermore, alterations in
intracellular nucleotide sugar levels can also modulate glycosylation
patterns. It is observed that pathological hypoxic microenviron 
ments frequently occur in solid cancers and inflammatory foci.
Hypoxic conditions dramatically change gene expression profiles, by
activating hypoxia inducible factor 1, which mediates adaptive
cellular responses. Hypoxia induced glycosyltransferases and
nucleotide sugar transporters have been shown to modulate
glycosylation patterns that are part of the mechanism associated
with cancer metastasis. Hypoxia inducible factor 1 also induces
the expression of glucose transporters and various types of
glycolytic enzymes, leading to shifts in glucose metabolic patterns.
This fact strongly suggests that hypoxic conditions are an impor 
tant factor in modulating various nucleotide sugar biosynthetic
pathways. This review discusses some of the current thinking of
how hypoxia alters glucose metabolic fluxes that can modulate
cellular glycosylation patterns and consequently modify cellular
functions, particularly from the standpoint of the N acetylglucos 
amine cycle, a part of the “Glycan cycle”.
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Biosynthetic Pathways of Uridine Diphosphate (UDP) N 
acetylglucosamine (GlcNAc)
Glucose is used as an energy source to produce adenosine
triphosphate (ATP) through metabolic processes, such as
glycolysis and cellular respiration. The free energy, generated by
the hydrolytic cleavage of the high-energy phosphate linkages of
ATP, is then used to drive various cellular activities. However,
glucose is essential not only as an energy source but also a meta-
bolic precursor of nucleotide sugars, which are utilized as donor
substrates in protein glycosylation. Glycosylation, one of the most
abundant posttranslational modification reactions, is necessary, in
terms of protein stability, as well as the localization and trafficking
of the proteins. Because approximately 50% of all known proteins
in eukaryotes are glycosylated,(1) the fine tuning of glycosylation is
important for maintaining biological systems in a normal context.
Glucose, after its incorporation into the cells via glucose trans-
porters (GLUTs), is initially converted to glucose-6-phosphate
by hexokinases, and a portion of the glucose-6-phosphate is then
metabolized via the pentose phosphate pathway, and this leads to
production of nucleotides, including uridine triphosphate (UTP),
guanosine triphosphate (GTP) and cytidine triphosphate (CTP),
which are structural components of diverse nucleotide sugars,
such as UDP-GlcNAc, UDP-N-acetylgalactosamine and UDP-
glucuronic acid, guanosine diphosphate (GDP)-mannose and GDP-
fucose, and cytidine monophosphate (CMP)-N-acetylneuraminic
acid (CMP-NeuAc), respectively, or is used in glycogen synthesis
to store surplus glucose in the form of glycogen in cells (Fig. 1).
In addition, under steady state conditions, approximately 1–3%
of the glucose-6-phosphate enters the hexosamine biosynthetic
pathway after conversion to fructose-6-phosphate,(2) while the
remaining glucose-6-phosphate is metabolized by glycolysis after
conversion to fructose-6-phosphate (Fig. 1). In the hexosamine
biosynthetic pathway, fructose-6-phosphate is first converted
into glucosamine-6-phosphate by glutamine-fructose-6-phosphate
amidotransferases (GFAT), the rate-limiting enzyme of the
hexosamine biosynthetic pathway; and the glucosamine-6-
phosphate is then acetylated by glucosamine-6-phosphate N-
acetyltransferases (GNA) to form GlcNAc-6-phosphate, which
is isomerized to GlcNAc-1-phosphate and uridinylated by the
action of UDP-GlcNAc pyrophosphorylases (UAP) (Fig. 1). The
synthesized UDP-GlcNAc is transported to the Golgi apparatus
via the UDP-GlcNAc transporters,(3) and is then utilized as a donor
substrate for the N- and O-linked glycosylation of extracellular
and membrane proteins; alternatively, it is utilized in the cytosol
for the O-GlcNAc modification (O-GlcNAcylation) of intra-
cellular proteins.
Biological Activities of N Acetylglucosaminyltransferases
(GnTs)
In mammalian cells, proteins are modified with a variety of
glycans, which can be classified into two major groups, N- and O-
glycans.(1) N-glycans are linked to certain asparagine residues of
proteins that contain the Asn-X-Ser/Thr motif, whereas O-glycans
are attached to a subset of serine and threonine residues.(4) The
addition of GlcNAc from UDP-GlcNAc to N- and O-glycans
and O-GlcNAcylation is catalyzed by enzymatic activity of GnTs
and O-linked N-acetylglucosaminyltransferase (OGT), localized
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in the Golgi apparatus and cytosol, respectively. The formation of
branched structures and subsequent elongation and processing of
N-glycans by various types of GnTs alter the biological functions
of the glycoproteins(5) and are associated with a variety of dis-
orders, such as cancer and diabetes mellitus.(6,7)
As shown in Fig. 2, with respect to the GlcNAc cycle, the Golgi
apparatus contains at least two enzymes, GnT-V and GnT-III,
which play key roles in the processing of N-glycans.
GnT-V catalyzes the transfer of a GlcNAc unit from UDP-
GlcNAc to a α1,6-mannose in N-glycans to form a β1,6-branched
N-glycans, thus elongating the polylactosamine structure (Fig. 2),
which controls cell surface receptor residency and is associated
with some of the invasive characteristics associated with cancer
cells.(1,8,9) Indeed, the overexpression of GnT-V has been reported
to promote integrin α5β1-mediated cell migration.(10) It has been
also reported that GnT-V activity and the levels of β1,6-branched
N-glycans were increased in highly metastatic cancer cell lines.(11,12)
On the contrary, GnT-III catalyzes the addition of a GlcNAc
unit in a β1,4-linkage to the mannose residue at the base of the
trimannosyl core of an N-glycan, to produce a so-called “bisecting
GlcNAc” (Fig. 2).(13,14) The introduction of a bisecting GlcNAc
prevents the formation of a branched structure in N-glycans,
since other GnTs are not able to utilize an N-glycan with a
bisecting GlcNAc as a substrate.(15) The overexpression of GnT-III
suppresses α5β1 integrin-mediated cell spreading, migration and
the phosphorylation of focal adhesion kinase (FAK).(16) These
results suggest that GnT-III has antagonizing effects against GnT-V.
Additionally, Ohtsubo et al.(17) demonstrated that a loss of GnT-
IVa, which catalyzes the formation of a β4 GlcNAc linkage on
the α3-linked mannose of N-glycans, attenuates the half-life of
GLUT2 on the pancreatic β-cell surface, and the resulting impair-
ment of glucose-stimulated insulin secretion leads to metabolic
dysfunctions that are characteristic of type 2 diabetes.
Fig. 1. Outline of UDP GlcNAc synthetic pathways. UDP GlcNAc is synthesized by three glucose metabolic pathways, such as the pentose phos 
phate pathway and subsequent nucleotide synthesis, hexosamine biosynthetic pathway, and glycolysis, supplying UTP, glcosamine and acetyl group,
respectively. GLUT, Glucose transporter; Glc, glucose; P, phosphate; R, ribose; CTP, cytidine triphosphate; GTP, guanosine triphosphate; UTP, uridine
triphosphate; GnT, N acetylglucosaminyltransferase; OGT, O linked GnT; Fruc, fructose; GlcN, glucosamine; GlcNAc, N acetylglucosamine; CoA,
coenzyme A; ManNAc, N acetylmannose; NeuAc, N acetylneuraminic acid; G6PD, glucose 6 phosphate dyhydrogenase; GFAT, glutamine Fruc 6 P
amidotransferase; GNA, Glc 6 P N acetyltransferase; UAP, UDP GlcNAc pyrophosphorylase; PFK, phosphofructokinase; GNE, UDP GlcNAc 2 epimerase/
ManNAc kinase.
Fig. 2. Glycosylation reactions catalyzed by the actions by GnT III and
GnT V. The enzymatic products by GnT III and GnT V are designated as
bisecting GlcNAc and β1,6 GlcNAc branch, respectively.doi: 10.3164/jcbn.11 015FR
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Regulation of Glycosylation via GlcNAc Cycle
Furthermore, alterations in intracellular nucleotide sugar levels
can also modulate glycosylation patterns (Fig. 3),(18) because GnTs
have different Km values for UDP-GlcNAc. Elevated intracellular
UDP-GlcNAc enhances the activities of GnT-V and GnT-IV,
which have higher Km values; however, low levels diminished
the activities. In fact, it was demonstrated that the formation
of  β1,6-branched  N-glycans in Jurkat T-cells is stimulated by
supplementation of metabolic precursors of the hexosamine bio-
synthetic pathway, including glucose, GlcNAc, glutamine, aceto-
acetate, ammonia and uridine, and regulates autoimmune reactions
of T-cells.(19) Furthermore, hyperglycemia involves an enhance-
ment in the hexosamine biosynthetic pathway activity and O-
GlcNAcylation levels, resulting in an enhanced susceptibility to
apoptosis of pancreatic β-cells.(20) Thus, glycosylation is affected
not only by the levels of expression of a single GnT enzyme but
rather by a magnitude factors, including the levels of mono-
oligosaccharides, nucleotide sugars, and nucleotide sugar trans-
porters, the localization of GnTs and nucleotide sugar levels in the
Golgi, transcription factors, the pro-form and mature form of
glycoproteins, and the structure of cell surface glycoproteins
(Fig. 3).(8) These components of the “GlcNAc cycle”, a part of
the “Glycan cycle”, should be considered in detecting changes in
dynamic glycan metabolism (Fig. 3).(8)
Hypoxia and Glycosylation
Pathological hypoxic microenvironments, which are observed
in many cases of solid cancers and inflammatory foci, dramati-
cally change gene expression profiles, and confer various malig-
nant characteristics to cancer cells. Hypoxia-inducible factor-1
(HIF-1) plays key roles in adaptive responses of cells under
hypoxic conditions through its transcription activity. The HIF-1
protein is a heterodimer, composed of a constitutively expressed
subunit of HIF-1β and an oxygen-dependently regulated subunit
of HIF-1α(21) (Fig. 4). The expression of HIF-1α is predominantly
regulated at posttranslational level. Under oxygen-sufficient
conditions, prolyl residues 402 and 564 in the N-terminal domain
of HIF-1α protein are hydroxylated by the actions of prolyl
hydroxylases (PHD) in an oxygen-dependent manner (Fig. 4).
This enables the binding of E3 ubiquitin ligase Von Hippel-Lindau
to HIF-1α, and leads to proteasomal degradation of the HIF-1α
protein (Fig. 4). On the contrary, under hypoxic conditions,
because enzymatic activities of PHDs are reduced, the HIF-1α
protein is stabilized and is translocated to the nucleus, where
induces gene expression (Fig. 4). Furthermore, in this process,
it has been demonstrated that reactive oxygen species (ROS)
generated from mitochondria under conditions of hypoxia is
required for stabilization of the HIF-1α protein.(22)
It is well known that hypoxic microenvironments dramatically
shift the pattern of intracellular glucose metabolism from aerobic
cellular respiration to anaerobic glycolysis. Under hypoxic condi-
tions, the expression of GLUT1 and various types of the rate-
limiting enzymes of glycolysis, such as phosphofructokinases
(PFK), aldolases (ALD), phosphoglycerate kinases (PGK), enolases
(ENO) and lactate dehydrogenases (LDH), are markedly trans-
activated by HIF-1 (Fig. 4). The resulting increased glucose
uptake and activation of glycolysis are highly important com-
pensatory responses against a reduction in intracellular ATP levels
due to the hypoxic inhibition of cellular respiration.
In a previous study, Koike et al.(23) reported that hypoxia
increases the levels of cell surface sialyl Lewis x and sialyl Lewis
a determinants, which are specific ligands for E-selectin, and
Fig. 3. Schmatic drawing of GlcNAc cycle (modified version of Ref. 18). Glycosylation is affected by various factors as described in text, and the pro 
form is converted to the mature form of glycoproteins by various glycosyltransferases and then localized on the cell surface such as integrin. The
intracellular levels of UDP GlcNAc and its precursor metabolites in sugar metabolism affect branching formation of N linked glycans, because
GlcNAc transferases have different apparent Km values for UDP GlcNAc. Also, the addition of O GlcNAc to proteins is highly responsive to UDP 
GlcNAc levels, and O GlcNAclyated or phosphoylated proteins function in a reciprocal relationship as a transcriptional regulator. GnT, N 
acetylglucosaminyltransferase; ST, sialyltransferase; GalT, galactosaminyltransferase; FucT, fucosyltransferase; GLUT, glucose transporter; Glc 6 P,
glucose 6 phosphate; Fruc 6 P, fructose 6 phosphate; GlcN 6 P, glucosamine 6 phosphate; ER, endoplasmic reticulum. J. Clin. Biochem. Nutr. | January 2011 | vol. 48 | no. 1 | 23
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also increases the transcription of fucosyltransferase VII (FUT7),
sialyltransferase ST3Gal-I and UDP-Gal transporter 1, which are
involved in the synthesis of the carbohydrate ligands of endo-
thelial E-selectin. In contrast, hypoxia dramatically shifts the
glucose metabolic pattern, which should affect intracellular
nucleotide sugar levels, particularly UDP-GlcNAc, and would
lead to alterations in glycan structures and cellular functions.
Therefore, how hypoxia alters glucose metabolic fluxes that can
modulate cellular glycosylation patterns and consequently modify
cellular functions, are discussed, with emphasis on the contribu-
tion of the GlcNAc cycle.
Hypoxia and UDP GlcNAc
It is unclear how hypoxic microenvironments affect the bio-
synthetic machinery of the nucleotide sugars. At present, there
is only one report dealing with a regulatory mechanism of the
hexosamine biosynthetic pathway in response to hypoxia. Manzari
et al.(24) demonstrated that hypoxia increased both mRNA and the
expressions of the corresponding protein, GFAT, the rate-limiting
enzyme of the hexosamine biosynthetic pathway. This study
concluded that the transcriptional activity of the GFAT gene is
directly regulated by HIF-1. We have also confirmed, using
RAW264.7 cells (a murine macrophage cell line), that hypoxic
exposure results in an increase in the mRNA levels of GFAT1
but the mRNA levels of other enzymes of the hexosamine
biosynthetic pathway downstream of GFAT1, such as GNA1,
UAP1 and GlcNAc kinase (NAGK) remain unchanged (un-
published data). These results imply that the biosynthesis of UDP-
GlcNAc should be promoted in cells under hypoxic conditions.
Thus, we recently determined changes in intracellular UDP-
GlcNAc levels in response to hypoxia, using ion-pair reversed-
phase high performance liquid chromatography (HPLC)(25) and
liquid chromatography-mass spectrometry (LC-MS). Surprisingly,
the intracellular level of UDP-GlcNAc was reduced by approxi-
mately 50% in cells exposed to hypoxia (unpublished data). These
findings suggest that activation of the hexosamine biosynthetic
pathway in response to hypoxia is not reflected  in the intracellular
abundance of UDP-GlcNAc.
In order to clarify hypoxia-induced alterations in the synthetic
pathway of UDP-GlcNAc, we analyzed changes in the metabolic
flow of glucose in response to hypoxia using unpublished LC-MS
methods after labeling the starting glucose at C-6 with 13C. The
ratio of metabolic flow was calculated from the intensity of the
isotopic pattern of 13C6-labeled nucleotide sugar in the mass
spectrum. It was found that a signal intensity 6 mass units higher
than that for ordinary UDP-GlcNAc in hypoxic cells was similar
to that in normoxic cells. This result indicates that metabolic flow
of the hexosamine biosynthetic pathway is maintained under
hypoxic conditions, because the mass shift of 6 reflects UDP-
GlcNAc, in which the glucosamine (hexose), was replaced by a
13C6-labeled molecule. However, the signal corresponding to 5
mass and 13 mass higher UDP-GlcNAc in hypoxic cells was
markedly weaker than that in normoxic cells. The five mass shift
reflects the replacement of ribose (pentose) in UDP and 13 mass
shift reflects that of all of components, including 13C5-ribose, 13C6-
glucosamine and the 13C2-labeled acetyl group. 13C5-ribose and
13C2-acetyl group is incorporated by the enzymatic activity of
UAP and GNA, respectively. Under oxygen-sufficient conditions,
acetyl-CoA is synthesized from pyruvate, a final product of
glycolysis, by pyruvate dehydrogenase. When intracellular oxygen
concentration is decreased, HIF-1 activates the transcription of
pyruvate dehydrogenase kinases (PDK), which neutralizes the
activity of pyruvate dehydrogenase(26) (Fig. 4). As a result, the
production of acetyl-CoA and its translocation to the tricarboxylic
acid (TCA) cycle is suppressed. This reaction is very important
in terms of the inhibition of oxygen consumption. This also
may cause the suppression in the addition of an acetyl group to
glucosamine, thus leading to an overall reduction in UDP-GlcNAc
production. Hisanaga et al.(27) reported that, when neonatal rats
are exposed to conditions of acute hypoxia exposure, a variety of
nucleotides in the brain, such as ATP, GTP, UTP and CTP are
decreased, and subsequent normoxic exposure restored these
nucleotide levels. The reduction in intracellular nucleotide levels
Fig. 4. Typical expression regulatory mechanism of HIF 1 protein and its possible roles in hypoxia induced reduction in GlcNAc cycle activity. HIF 1
activates a variety of proteins responsible for adaptation to hypoxia, including glycolytic enzymes (phosphofructokinase (PFK) etc.), through its
transcription activity. HIF 1 also activates the transcription of pyruvate dehydrogenase kinases (PDK), which neutralize the activity of pyruvate
dehydrogenase.(26) This may lead to the suppression of acetyl CoA production and result in reduction in intracellular UDP GlcNAc level. The anterior
pharynx defective (APH) 1, a component of γ secretase induced by HIF 1, increases the activity of γ secretase,(35) which has been shown to cleave
GnT V protein residing at Golgi lumen and induce extracellular secretion of GnT V.(33,34)doi: 10.3164/jcbn.11 015FR
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by hypoxic exposure may inhibit the addition of UDP to GlcNAc.
On the contrary, it is suspected that a diverging pathway of
nucleotide sugar synthesis is activated in response to hypoxia.
A portion of the synthesized UDP-GlcNAc has been shown to
be epimerized by UDP-GlcNAc 2-epimerase (GNE), and is
then supplied to the synthetic pathway of CMP-NeuAc,(28) which
leads to cell surface sialylation (Fig. 3). We found that, when
RAW264.7 cells were exposed to hypoxic conditions or treated
with the hypoxia-mimetic agent cobalt chloride (CoCl2), the intra-
cellular level of CMP-NeuAc, unlike UDP-GlcNAc, was signifi-
cantly increased (unpublished data). From these results, analyses
of the downstream pathway(s) of UDP-GlcNAc may reveal the
mechanism behind the hypoxia-induced reduction of UDP-GlcNAc.
Hypoxia and GnTs
It is very important to clarify the mechanism by which GnTs is
controlled, because the levels of such enzymes directly affect the
patterns of glycosylation and is partly responsible for the GlcNAc
cycle. However, to date, the transcriptional regulatory mechanism
of GnT genes has not been fully elucidated. Meanwhile, our group
previously demonstrated that the expression of the Mgat5 gene,
encoding GnT-V, is regulated by a member of the E-twenty
six (Ets) family of transcription factors, Ets-1.(29,30) It was also
reported that the expression of the ETS1 gene is regulated by
HIF-1.(31) These findings suggest the indirect induction of GnT-V
expression by HIF-1 in cells that are exposed to hypoxia. However,
the level of Mgat5 mRNA was relatively decreased by hypoxic
exposure in the case of RAW264.7 cells (unpublished data). This
may be because Ets-1 protein is constitutively expressed in
monocytes and macrophages, and, as a result, the expression of
Ets-1 is not inducible in response to hypoxia in these cells.(32)
These findings indicate that the expression of GnT-V is not
induced in hypoxic macrophages. Furthermore, we recently
reported that the enzymatic activity of GnT-V was gradually
reduced along with hypoxic exposure time in RAW264.7 cells,
while no GnT-III activity was detected in these cells (unpublished
data). On the other hand, it has been demonstrated that the GnT-V
protein, residing in the Golgi lumen, is cleaved by γ-secretase
(a protease complex composed of presenilin, nicastrin, anterior
pharynx-defective (APH)-1 and presenilin enhancer (PEN)-2),
and the secreted type of GnT-V has angiogenesis effects.(33,34)
Wang et al.(35) demonstrated that HIF-1 regulates the expression
of APH-1A, a component of γ-secretase, and the γ-secretase-
mediated secretion of amyloid β (Fig. 4). Thus, it is necessary to
examine, not only transcriptional regulation but also the post-
translational modification of GnTs.
Conclusion
Hypoxia reduces the activity of a portion of the GlcNAc cycle,
including intracellular UDP-GlcNAc levels and GnT-V activity.
Analysis of the metabolic flow of glucose using unpublished
LC-MS methods using 13C6-labeled glucose (Nakajima et al.,
manuscript in preparation) indicates that the hypoxia-induced
reduction in intracellular UDP-GlcNAc levels is caused by the
suppression of the addition of an acetyl group to glucosamine and
intracellular nucleotide levels.
To clarify physiological significances of these hypoxia-induced
reductions in GlcNAc cycle activity, it is essential to analyze
whether or not the levels of β1,6-branced N-glycans of the target
cell surface proteins are reduced. Furthermore, a better under-
standing of the mechanisms associated with GlcNAc cycle inacti-
vation in response to hypoxia is important, because recovery
experiments of GlcNAc cycle activities are essential in terms of
identifying whether the resultant carbohydrate structural altera-
tions contribute the hypoxia-induced changes in cellular function.
Thus, it needs glucose metabolomic analysis regarding the UDP-
GlcNAc biosynthetic pathways, including the pentose phosphate
pathway and subsequent nucleotide synthesis, hexosamine bio-
synthetic pathway, and glycolysis. Finally, other components
of the glycan cycle, including nucleotide sugar transporters, the
localization of GnTs and nucleotide sugar levels in the Golgi
should also be considered, and an understanding of the glycan
cycles will promise further advancements in the future for the field
of glycobiology.(8)
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